Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 4Completed 3Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Rectal Neoplasms 1Pancreatic Neoplasms 1Colonic Neoplasms 1Clinical Stage I Gastric Cancer AJCC v8 1Borderline Resectable Pancreatic Adenocarcinoma 1

Interventions

Fluorouracil 11Leucovorin 10Oxaliplatin 9Bevacizumab 6Irinotecan 5Capecitabine 3regorafenib 2aflibercept 2Folfox protocol 2Exercise 2Chemotherapy, Adjuvant 2Cetuximab 2Biopsy 2Atorvastatin 2tucatinib 1trifluridine tipiracil drug combination 1trastuzumab biosimilar HLX02 1sulindac sulfone 1sargramostim 1retrovector encoding mutant anti-cyclin G1 1poly ICLC 1pidilizumab 1pembrolizumab 1p53 peptide 264-272, human 1nilotinib 1monalizumab 1lonafarnib 1irofulven 1infigratinib 1grp protein, Drosophila 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Colonic Neoplasms × dehydroftorafur × Clear all
NCT02575508 2016-05-20

Pan FGFR Kinase Inhibitor BGJ398 and Combination Chemotherapy in Treating Patients With Untreated Metastatic Pancreatic Cancer

Roswell Park Cancer Institute

Phase 1/2 Withdrawn
Gastrointestinal

Colonic Neoplasms, Pancreatic Neoplasms, Rectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡